By admin 
The pharmaceutical landscape was jolted this week by a dual-pronged assault of corporate instability at one of Europe’s largest drugmakers and a radical shift in U.S. federal drug-pricing policy. In Basel, the executive suite at Novartis is facing an existential crisis as major institutional investors demand a complete overhaul of the board of directors following a catastrophic week on the stock market. Simultaneously, in Washington D.C., the Centers for Medicare and Medicaid Services (CMS) under the leadership of Administrator Mehmet Oz has signaled a new era of "bespoke" pricing negotiations that trade domestic tariff relief for global price parity. These developments represent a pivotal moment for the industry, where the high-stakes gamble of multi-billion-dollar acquisitions is meeting a new, transactional form of government regulation.
The turmoil at Novartis began in earnest after the company’s share price plummeted to a record low, wiped out by the compounding effects of two major clinical disappointments. The most stinging of these was the revelation that a late-stage study for a high-profile muscle-wasting disorder drug had failed to meet its primary endpoints. The drug, a cornerstone of Novartis’s $12 billion acquisition of the biotechnology firm Avidity, was supposed to be the jewel in the crown of the company’s "pure-play" strategy—a move away from generics and consumer health toward high-margin, innovative medicines. The failure of this trial has not only cast doubt on the valuation of the Avidity deal but has also raised systemic questions about Novartis’s due diligence processes and its ability to integrate and execute on external R&D pipelines.
Compounding the misery for Novartis was the lackluster performance of pelacarsen, an antisense oligonucleotide designed to reduce levels of Lipoprotein(a), a known risk factor for cardiovascular disease. While the medical community had high hopes for pelacarsen as a first-in-class treatment for a massive untreated patient population, the most recent data shared with investors failed to demonstrate the robust clinical benefit required to justify its projected blockbuster status. With two of its most anticipated growth drivers now stalled or derailed, the company’s market capitalization has seen a contraction that has left its largest backers fuming.
David Samra, the influential managing director at Artisan Partners and a founding partner of the International Value Group, has emerged as the voice of this shareholder discontent. In a scathing critique of the current leadership, Samra called for a significant "shake-up" of the Novartis board, arguing that corporate governance has failed to provide the necessary friction to prevent reckless capital allocation. According to Samra, successive chairmen at Novartis have overseen a string of acquisitions that have failed to yield the promised returns, suggesting that the board’s oversight of M&A is fundamentally broken. His public demand for change is a rare and aggressive move in the typically reserved world of European pharmaceutical investment, signaling that the "wait and see" approach of institutional investors has reached its limit.
The critique from Artisan Partners highlights a broader trend in the industry: the "acquisition trap." As large pharmaceutical companies face patent cliffs for their legacy products, they are increasingly forced to buy growth by acquiring smaller biotech firms at massive premiums. However, as the Novartis-Avidity situation demonstrates, the biological risks inherent in drug development do not vanish just because a larger company is footing the bill. Critics argue that the Novartis board became too enamored with the promise of RNA-based therapeutics and failed to adequately stress-test the clinical data before committing $12 billion of shareholder capital.
While Novartis struggles with internal governance, the external environment in its largest market, the United States, is undergoing a profound transformation. Mehmet Oz, the CMS Administrator appointed by the Trump administration, has moved aggressively to redefine the relationship between the federal government and the pharmaceutical industry. Speaking at a recent industry summit, Oz confirmed that the administration is actively pursuing a series of "bespoke" drug-pricing deals aimed at lowering costs for public programs while bypassing the more rigid structures of previous legislative frameworks.
According to Oz, the administration has already secured more than two dozen voluntary agreements with various pharmaceutical companies. These deals are characterized by their flexibility and their transactional nature. In essence, the Trump administration is offering a "grand bargain": drugmakers agree to lower the prices they charge Medicare and Medicaid, ensuring that U.S. taxpayers are not paying significantly more than patients in other developed nations like the United Kingdom, France, or Germany. In exchange, the administration provides these companies with relief from the broad-based tariffs that have become a hallmark of current U.S. trade policy.
This "Prices-for-Tariffs" swap represents a significant departure from the drug-pricing provisions of the 2022 Inflation Reduction Act (IRA). While the IRA relied on mandatory negotiations for a select list of high-spend drugs, the Oz-led CMS is utilizing executive leverage to create a more dynamic, albeit unpredictable, pricing environment. For many pharmaceutical executives, the prospect of avoiding 10% to 20% tariffs on imported active pharmaceutical ingredients (APIs) or finished dosage forms is a powerful incentive to come to the negotiating table. However, the "bespoke" nature of these deals—where each contract is tailored to the specific portfolio of the company—has created a sense of unease regarding long-term price stability and transparency.
Industry analysts are divided on the implications of this new policy. Proponents argue that the voluntary nature of the agreements preserves the "spirit of innovation" by allowing companies to negotiate terms that reflect the unique value of their products. They also point out that linking drug prices to trade policy provides the administration with a "carrot-and-stick" approach that can be adjusted more quickly than statutory law. On the other hand, skeptics worry that this creates a "pay-to-play" atmosphere where the largest companies with the most significant lobbying presence can secure more favorable deals, potentially disadvantaging smaller biotech firms that lack the scale to navigate complex trade-and-pricing negotiations.
The situation at Novartis serves as a cautionary tale for how these two forces—internal R&D failure and external regulatory pressure—can collide. If Novartis had been more successful in its clinical trials, it might have had the leverage to negotiate more effectively with the CMS. Instead, the company finds itself in a weakened position, facing both a shareholder revolt and a government that is increasingly demanding price concessions. The "tiramisu" coffee being served on the Pharmalot campus might be sweet, but the mood in the boardroom in Basel is decidedly bitter.
The broader market is now watching closely to see if other major shareholders will join Artisan Partners in their call for a board shake-up. Names like BlackRock and Vanguard, which hold significant stakes in Novartis, have traditionally been more conservative in their approach to activist intervention. However, the sheer scale of the recent share price collapse may force their hand. If a formal proxy battle ensues, it could lead to a fundamental restructuring of how Novartis identifies and values its acquisition targets, potentially cooling the red-hot M&A market for biotech firms specializing in muscle-wasting and cardiovascular treatments.
Furthermore, the "Oz Doctrine" at CMS is expected to expand. Reports suggest that the administration is looking to apply this bespoke model to high-cost biologics and cell therapies, areas where pricing has historically been most resistant to downward pressure. By leveraging the threat of tariffs on a global scale, the administration is effectively attempting to "import" the lower price points found in socialized healthcare systems without implementing a formal domestic price control board. This strategy relies on the fact that most major pharmaceutical companies are global entities that rely on complex, cross-border supply chains that are highly sensitive to trade barriers.
As the industry moves into the final quarter of 2026, the twin themes of governance and "deal-making" regulation are set to dominate the narrative. For Novartis, the path forward requires more than just a new cup of coffee; it requires a restoration of investor confidence that can only come from clinical success or a radical change in leadership. For the rest of the industry, the message from Washington is clear: the price of doing business in the American market now includes a seat at the negotiating table, with the shadow of the tariff man looming over every proposal. The "pleasant start" to the day on the Pharmalot campus may soon give way to a stormy season of corporate restructuring and geopolitical maneuvering that will reshape the pharmaceutical world for years to come.
